These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 21904312)

  • 21. Japanese firms broaden investment focus to early biotech.
    Louët S; Sipp D
    Nat Biotechnol; 2004 Aug; 22(8):931-2. PubMed ID: 15286631
    [No Abstract]   [Full Text] [Related]  

  • 22. A venture capital view of challenges, opportunities, and innovation in biomedical research.
    Ratcliffe LT
    Clin Pharmacol Ther; 2011 Feb; 89(2):174-6. PubMed ID: 21252935
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Early-stage returns?
    Booth BL
    Nat Biotechnol; 2006 Nov; 24(11):1335-40. PubMed ID: 17093473
    [TBL] [Abstract][Full Text] [Related]  

  • 24. 1Q13--Stocks reach all-time high.
    Yang W
    Nat Biotechnol; 2013 May; 31(5):378. PubMed ID: 23657383
    [No Abstract]   [Full Text] [Related]  

  • 25. The rise of European venture capital for biotechnology.
    Howell M; Trull M; Dibner MD
    Nat Biotechnol; 2003 Nov; 21(11):1287-91. PubMed ID: 14595356
    [No Abstract]   [Full Text] [Related]  

  • 26. A reprise for collaborative financing in biotech.
    Ransom J
    Nat Biotechnol; 2006 Aug; 24(8):873-4. PubMed ID: 16900110
    [No Abstract]   [Full Text] [Related]  

  • 27. Diversa restructures, raising question over bioprospecting.
    Sheridan C
    Nat Biotechnol; 2006 Mar; 24(3):229. PubMed ID: 16525364
    [No Abstract]   [Full Text] [Related]  

  • 28. US credit crunch impacts biotech across the globe.
    Mitchell P
    Nat Biotechnol; 2008 Apr; 26(4):359-60. PubMed ID: 18391997
    [No Abstract]   [Full Text] [Related]  

  • 29. VC funding hits high in Q1.
    Lawrence S
    Nat Biotechnol; 2007 May; 25(5):496. PubMed ID: 17483825
    [No Abstract]   [Full Text] [Related]  

  • 30. Mixed results in Q1.
    Lawrence S
    Nat Biotechnol; 2005 May; 23(5):518. PubMed ID: 15877059
    [No Abstract]   [Full Text] [Related]  

  • 31. The stampede to convertibles.
    Jacobs T
    Nat Biotechnol; 2003 Aug; 21(8):855. PubMed ID: 12894195
    [No Abstract]   [Full Text] [Related]  

  • 32. When your stock takes a nosedive.
    Jacobs T
    Nat Biotechnol; 2006 Feb; 24(2):144. PubMed ID: 16465152
    [No Abstract]   [Full Text] [Related]  

  • 33. Public companies get creative in raising finance.
    Hodgson J
    Nat Biotechnol; 2010 Apr; 28(4):301-2. PubMed ID: 20379161
    [No Abstract]   [Full Text] [Related]  

  • 34. Capital faucet wide-open. Firms' healthcare-related investments up 16% in first half.
    Pallarito K
    Mod Healthc; 1997 Sep; 27(35):76. PubMed ID: 10170390
    [No Abstract]   [Full Text] [Related]  

  • 35. Europe needs a single, deep capital market.
    Hodgson J
    Nat Biotechnol; 2002 Oct; 20(10):960-1. PubMed ID: 12355101
    [No Abstract]   [Full Text] [Related]  

  • 36. PEGging biotech growth.
    Jacobs T
    Nat Biotechnol; 2006 May; 24(5):506. PubMed ID: 16680127
    [No Abstract]   [Full Text] [Related]  

  • 37. Could bank loans solve Europe's biotech financing slump?
    Mitchell P
    Nat Biotechnol; 2005 Dec; 23(12):1459-60. PubMed ID: 16333276
    [No Abstract]   [Full Text] [Related]  

  • 38. Biotech jostles with pharma for slice of HIV market.
    Katsnelson A
    Nat Biotechnol; 2006 Jan; 24(1):3-4. PubMed ID: 16404375
    [No Abstract]   [Full Text] [Related]  

  • 39. Sustaining agbiotechnology through lean times.
    McElroy D
    Nat Biotechnol; 2003 Sep; 21(9):996-1002. PubMed ID: 12949560
    [No Abstract]   [Full Text] [Related]  

  • 40. The further evolution of biotech.
    Nagle T; Berg C; Nassr R; Pang K
    Nat Rev Drug Discov; 2003 Jan; 2(1):75-9. PubMed ID: 12509762
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.